<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732020000600520</article-id>
<article-id pub-id-type="doi">10.32385/rpmgf.v36i6.12608</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Vacina contra o herpes zoster em Portugal]]></article-title>
<article-title xml:lang="en"><![CDATA[Herpes zoster vaccine in portugal]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conde]]></surname>
<given-names><![CDATA[Margarida Gil]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Raquel Carmona]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ACeS Lisboa Central USF Vasco da Gama ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>6</numero>
<fpage>520</fpage>
<lpage>523</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732020000600520&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732020000600520&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732020000600520&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Herpes zoster (HZ), também conhecido por zona, é uma doença causada pela reativação do vírus varicella zoster (VZ). O aumento da idade pode ser um fator de risco para HZ e as suas maiores complicações são a nevralgia pós-herpética (NPH) e o herpes zoster ophtalmicus (HZO). A vacinação para HZ é um método eficaz e seguro para a prevenção da doença em doentes imunocompetentes e são vários os estudos e revisões que suportam a indicação para vacinação da população a partir dos 60 anos. Embora existam duas vacinas disponíveis no mercado norte americano, em Portugal apenas se encontra aprovada a vacina viva atenuada (VVA) - Zostavax®. Apesar de ainda não existirem muitos estudos, os já realizados parecem mostrar superioridade no custo-eficácia da vacina recombinante (VR), Shingrix®, quando comparada com a VVA. Estima-se que 10-30% da população portuguesa seja afetada pela reativação do vírus pelo que urge a importância de se avaliar o real impacto de HZ na população e, caso este se verifique relevante, estudar a necessidade de recomendar a vacinação a todos os doentes com idade superior a 60 anos e aprovar a nova VR.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Herpes zoster (HZ), also known as shingles, is a disease caused by the reactivation of the varicella-zoster (VZ) virus. Increasing age can be a risk factor for the development of HZ, which has, as main complications, postherpetic neuralgia (PHN) and herpes zoster ophtalmicus (HZO). Vaccination against VZ is an effective and safe method for prevention in immunocompetent patients and it is recommended, according to many studies, for patients over 60 years old. Although there are two vaccines available in the United States of America, in Portugal only the live-attenuated vaccine (LAV), Zostavax®, was approved. Despite the lack of studies, the ones that were conducted seem to demonstrate the cost-effectiveness superiority of the recombinant vaccine (RV), Shingrix®, when compared to the LAV. It is estimated that 10-30% of the Portuguese population is affected by the reactivation of the virus, which demonstrates the need to evaluate the real impact of the disease on our population. It is also necessary to study the benefits of recommending vaccination to every immunocompetent patient above 60 years old and of approving the new RV.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Vacina do herpes zoster]]></kwd>
<kwd lng="pt"><![CDATA[Neuralgia pós-herpética.]]></kwd>
<kwd lng="en"><![CDATA[Herpes zoster vaccine]]></kwd>
<kwd lng="en"><![CDATA[Postherpetic neuralgia.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sampathkumar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Drage]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster (shingles) and postherpetic neuralgia]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2009</year>
<volume>84</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>274-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmader]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster]]></article-title>
<source><![CDATA[Clin Geriatr Med]]></source>
<year>2016</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>539-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Shingles (herpes zoster) vaccine (Zostavax(r)) a review in the prevention of herpes zoster and postherpetic neuralgia]]></article-title>
<source><![CDATA[BioDrugs]]></source>
<year>2016</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>243-54</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bader]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster diagnostic, therapeutic, and preventive pproaches]]></article-title>
<source><![CDATA[Postgrad Med]]></source>
<year>2013</year>
<volume>125</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>78-91</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yawn]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for herpes zoster a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2017</year>
<volume>92</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1806-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dayan]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Peleg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster typical and atypical presentations]]></article-title>
<source><![CDATA[Postgrad Med]]></source>
<year>2017</year>
<volume>129</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>567-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liesegang]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2008</year>
<volume>115</volume>
<numero>2 Suppl</numero>
<issue>2 Suppl</issue>
<page-range>S3-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmader]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster in older adults]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2001</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1481-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gabutti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Valente]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhdari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lupi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of herpes zoster and its complications from the clinic to the real-life experience with the vaccine]]></article-title>
<source><![CDATA[J Med Microbiol]]></source>
<year>2016</year>
<volume>65</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1363-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>National Advisory Committee on Immunization</collab>
<source><![CDATA[Herpes zoster (shingles) vaccine: Canadian immunization guide]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Ottawa ]]></publisher-loc>
<publisher-name><![CDATA[Public Health Agency Canada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Australian Technical Advisory Group on Immunisation</collab>
<source><![CDATA[The Australian Immunisation Handbook provides clinical advice for health professionals on the safest and most effective use of vaccines in their practice]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Canberra ]]></publisher-loc>
<publisher-name><![CDATA[Australian Government Department of Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Haut Conseil de la Santé Publique</collab>
<source><![CDATA[Avis relatif à la vaccination des adultes contre le zona avec le vaccin Zostavax(r)]]></source>
<year>2013</year>
<publisher-name><![CDATA[Haut Conseil de la Santé Publique]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dooling]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Belongia]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines]]></article-title>
<source><![CDATA[MMWR Morb Mortal Wkly Rep]]></source>
<year>2018</year>
<volume>67</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>103-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willis]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Popmihajlov]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Saddier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Annunziato]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster vaccine live a 10 year review of post-marketing safety experience]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2017</year>
<volume>35</volume>
<numero>52</numero>
<issue>52</issue>
<page-range>7231-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Lal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kovac]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chlibek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Díez-Domingo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1019-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The herpes zoster subunit vaccine]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2016</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>265-71</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant zoster vaccine (Shingrix(r)) a review in herpes zoster]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2018</year>
<volume>35</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1031-40</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Trivedi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kavani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Medvedeva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[YX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1341-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tricco]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Zarin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Veroniki]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Nincic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older systematic review and network meta-analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2018</year>
<volume>363</volume>
<page-range>k4029</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gagliardi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Andriolo]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Torloni]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccines for preventing herpes zoster in older adults]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2016</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>CD008858</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>INFARMED</collab>
<source><![CDATA[Infarmed.pt]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[INFARMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Direção-Geral da Saúde</collab>
<source><![CDATA[Programa nacional de vacinação (2017)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[DGS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>Comissão de Vacinas da Sociedade de Infeciologia Pediátrica</collab>
<source><![CDATA[Recomendações sobre vacinas extra Plano Nacional de Vacinação: atualização 2018]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Sociedade Portuguesa de Pediatria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesquita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Froes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospital admissions for herpes zoster in Portugal between 2000 and 2010]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2013</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>531-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lecrenier]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Beukelaers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Colindres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[De Kesel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[De Sargher]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention]]></article-title>
<source><![CDATA[Expert Rev Vaccines]]></source>
<year>2018</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>619-34</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belchior]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lévy-Bruhl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Le Strat]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Herida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of a herpes zoster vaccination program among the French elderly people]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2019</year>
<volume>12</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2378-82</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rothberg]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determining the optimal vaccination schedule for herpes zoster a cost-effectiveness analysis]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2017</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>159-67</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Izurieta]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Wernecke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kelman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Forshee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2017</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>785-93</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blank]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Ademi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Szucs]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Schwenkglenks]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes zoster vaccine a health economic evaluation for Switzerland]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2017</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1495-504</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoshi]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Okubo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2017</year>
<volume>35</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>3264-71</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Varghese]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Van Oorschot]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Carrico]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2018</year>
<volume>36</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>5037-45</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Godeaux]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Chlibek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díez-Domingo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2087-96</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
